nach oben

Journal of Neuro-Oncology

Erschienen in:

01.07.2014 | TOPIC REVIEW & CLINICAL GUIDELINES

The role of cytoreductive surgery in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

verfasst von: Timothy Charles Ryken, Steven N. Kalkanis, John M. Buatti, Jeffrey J. Olson

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Question

Should patients with previously diagnosed malignant glioma who are suspected of experiencing progression of the neoplasm process undergo repeat open surgical resection?

Target population

These recommendations apply to adults with previously diagnosed malignant glioma who are suspected of experiencing progression of the neoplastic process and are amenable to surgical resection.

Recommendations

Level II

Repeat cytoreductive surgery is recommended in symptomatic patients with locally recurrent or progressive malignant glioma. The median survival in these patient diagnosed with glioblastoma is expected to range from 6 to 17 months following a second procedure.

It is recommended that the following preoperative factors be considered when evaluating a patient for repeat operation: location of recurrence in eloquent/critical brain regions, Karnofsky Performance Status and tumor volume.

Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 118:2163–2172

Easaw JC, Mason WP, Perry J et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (Toronto Ont) 18:e126–e136

Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107:207–212

Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC (2009) Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol 93:1–23

Olson JJ, Ryken T (2008) Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol 89:255–258

Zuniga RM, Torcuator R, Jain R et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336

Ammirati M, Galicich JH, Arbit E, Liao Y (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607–614

Barker FG, 2nd et al (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709–720; discussion 720–723

Berger MS, Tucker A, Spence A, Winn HR (1992) Reoperation for glioma. Clin Neurosurg 39:172–186

10.

Boiardi A et al (1999) Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Ital J Neurol Sci 20:43–48

11.

Brem H et al (1995) The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 26:111–123

12.

Carson KA, Grossman SA, Fisher JD, Shaw EG (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25:2601–2606

13.

Daneyemez M, Gezen F, Canakci Z, Kahraman S (1998) Radical surgery and reoperation in supratentorial malignant glial tumors. Minim Invasive Neurosurg 41:209–213

14.

Darakchiev BJ, Albright RE, Breneman JC, Warnick RE (2008) Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 108:236–242

15.

Dirks P, Bernstein M, Muller PJ, Tucker WS (1993) The value of reoperation for recurrent glioblastoma. Can J Surg 36(3):271–275

16.

Durmaz R et al (1997) Management of glioblastoma multiforme: with special reference to recurrence. Clin Neurol Neurosurg 99:117–123

17.

Guyotat J et al (2000) Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7:899–904

18.

Harsh GR 4th et al (1987) Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21:615–621

19.

Hau, P, Baumgart U, Pfeifer K et al (2003) Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 98:2678–2686

20.

Helseth R, Helseth E, Johannesen TB et al (2010) Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 122:159–167

21.

Landy HJ et al (1994) Retreatment of intracranial gliomas. South Med J 87:211–214

22.

Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP (2008) Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol 69:506–509; discussion 509

23.

Moser RP (1988) Surgery for glioma relapse. Factors that influence a favorable outcome. Cancer 62:381–390

24.

Muhling M, Krage J, Hussein S, Samii M (1999) Indication for repeat surgery of glioblastoma: influence of progress of disease. Front Radiat Ther Oncol 33:192–201

25.

Olson JJ et al (2008) Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neurooncol 90:293–299

26.

Park JK et al (2010) Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28:3838–3843

27.

Pinsker M, Lumenta C (2001) Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43–47

28.

Pool JL (1968) The management of recurrent gliomas. Clin Neurosurg 15:265–287

29.

Rostomily RC et al (1994) Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35:378–388; discussion 388

30.

Salcman M, Kaplan RS, Ducker TB, Abdo H, Montgomery E (1982) Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma. Neurosurgery 10:454–463

31.

Shrieve DC et al (1999) Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90:72–77

32.

Sipos L, Afra D (1997) Re-operations of supratentorial anaplastic astrocytomas. Acta Neurochir (Wien) 139:99–104

33.

Soults CB, Canute GS, Ryken TC (1998) Evidence-based review of the role of reoperation in the management of malignant glioma. Neurosurg Focus 4:e11

34.

Stromblad LG, Anderson H, Malmstrom P, Salford LG (1993) Reoperation for malignant astrocytomas: personal experience and a review of the literature. Br J Neurosurg 7:623–633

35.

Subach BR et al (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 45:17–22; discussion 22–23

36.

Vick NA, Ciric IS, Eller TW, Cozzens JW, Walsh A (1989) Reoperation for malignant astrocytoma. Neurology 39:430–432

37.

Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409

38.

Young B et al (1981) Reoperation for glioblastoma. J Neurosurg 55:917–921

39.

Brem H et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012

40.

Wallner KE et al (1989) Inability of computed tomography appearance of recurrent malignant astrocytoma to predict survival following reoperation. J Clin Oncol 7:1492–1496

41.

Haller JW, Ryken TC, Vannier MW (2001) Image-guided therapy: infrastructure for practical applications. Acad Radiol 8:888–897

42.

Amin V et al (2008) Therapy planning and monitoring of tissue ablation by high intensity focused ultrasound (HIFU) using imaging and simulation. Conf Proc IEEE Eng Med Biol Soc 2008:4471

43.

Stummer W et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576; discussion 564–576

44.

Nabavi A et al (2009) Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 65:1070-1076; discussion 1076–1077

45.

Assem M et al (2012) Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics. OMICS 16:113–122

46.

Foltz G et al (2006) Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 66:6665–6674

47.

Foltz G et al (2009) DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis. Oncogene 28:2667–2677

48.

Shah N et al (2011) Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One 6:e16146

49.

Solomon DA et al (2008) Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 68:10300–10306

50.

Solomon DA et al (2009) Sample type bias in the analysis of cancer genomes. Cancer Res 69:5630–5633

51.

Zaheer A, Sahu SK, Ryken TC, Traynelis VC (2007) Cis-parinaric acid effects, cytotoxicity, c-Jun N-terminal protein kinase, forkhead transcription factor and Mn-SOD differentially in malignant and normal astrocytes. Neurochem Res 32:115–124

Titel: The role of cytoreductive surgery in the management of progressive glioblastoma
A systematic review and evidence-based clinical practice guideline
verfasst von: Timothy Charles Ryken
Steven N. Kalkanis
John M. Buatti
Jeffrey J. Olson
Publikationsdatum: 01.07.2014
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1336-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The role of cytoreductive surgery in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

Abstract

Question

Target population

Recommendations

Level II

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Question

Target population

Recommendations

Level II

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

The role of imaging in the management of progressive glioblastoma

Introduction, rationale, and methodology

Glioblastoma at progression: therapy of a challenging problem addressed candidly with evidence-based techniques

The role of radiotherapy in the management of progressive glioblastoma

The role of targeted therapies in the management of progressive glioblastoma

The role of neuropathology in the management of progressive glioblastoma

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie